Chapter 3 Market and Technology Background
- Immunotherapy
- Towards Combination Immunotherapy
- Focusing on Cell-mediated Adaptive Immunity
- Fine Tuning Vs. Boosting Cancer Immunity
- Early Vs. Advanced Stage Cancer Immunotherapy
- Personalized Treatment Paradigm
- Clinically Significant Types of Cancers
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Stomach Cancer
- Leukemia
- Future of Immunotherapy in Cancer
- Infectious Diseases
- Immunotherapy against Autoimmune Disorders
- Immunotherapies against Infectious Diseases
- Biologics as Autoimmune Disorder Therapies
- Trends in Autoimmune Disorder Therapies
- Types of Immunotherapies
- Checkpoint Inhibitors
- Unmet Medical Needs
- New Biomarkers to Stratify Patients
- Relapse/Refractory Patients
- Treatment Efficacy and Tolerability
- Innovative Strategies
- Novel Targeted Approaches
- Monoclonal Antibodies
- Interleukins
- Interferons
Chapter 5 Impact of COVID-19 on the Pharmaceutical Industry
- Short-term Impact
- Change in Demand
- Shift of Communication and Promotions to Remote Interactions
- Changes to R&D
- Long-term Impact
- Delayed Approvals for Non-COVID-related Pharmaceutical Products
- Self-sufficiency in the Pharmaceutical Industry
- Changes in Consumption Trends in Health-related Products
Chapter 6 Market Breakdown by Product Type
- Overview
- Monoclonal Antibodies
- Market Overview
- Market Revenue
- Market Share
- Market by Region
- Market Overview
- Market Revenue
- Market Share
- Checkpoint Inhibitors
- Pembrolizumab
- Companion Diagnostic
- Clinical Trial Program
- Forecast for Pembrolizumab
- Nivolumab (Opdivo)
- Companion Diagnostic
- Clinical Trial Program
- Forecast for Nivolumab
- Atezolizumab (Tecentriq)
- Companion Diagnostic
- Clinical Trial Program
- Forecast for Atezolizumab
- Avelumab (Bavencio)
- Companion Diagnostic
- Clinical Trial Program
- Forecast for Avelumab
- Durvalumab (Imfinzi)
- Companion Diagnostic
- Clinical Trial Program
- Durvalumab Forecasts
- Yervoy (Ipilimumab)
- Market by Region
- Market Revenue
- Market Share
- Interferons and Interleukins
- Market Revenue
- Market by Region
- Market by Disease Area
List of Tables
Summary Table B: Global Market for Immunotherapy Drugs, by Region, Through 2025
Summary Table A: Global Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 1: Stages of Lung Cancer
Table 2: Biologics as Autoimmune Disorder Therapies
Table 3: Adverse Events Associated with Immune-Checkpoint Blockade
Table 4: Evolution of Monoclonal Antibodies
Table 5: Advantages and Disadvantages of Monoclonal Antibodies
Table 6: Murine Monoclonal Antibodies
Table 7: Chimeric Monoclonal Antibodies
Table 8: Humanized Monoclonal Antibodies
Table 9: Human Monoclonal Antibodies
Table 10: Selected Approved Interferon Alpha Analogs
Table 11: Global Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 12: Global Market for Monoclonal Antibodies, by Type, Through 2025
Table 13: Global Market Shares for Monoclonal Antibody Drugs, by Type, 2019
Table 14: Global Market for Monoclonal Antibody Drugs, by Region, Through 2025
Table 15: Global Market Shares for Monoclonal Antibody Drugs, by Region, 2019
Table 16: Global Market for Checkpoint Inhibitors, 2019-2025
Table 17: Pembrolizumab Approved Indications
Table 18: Nivolumab Approved Indications
Table 19: Atezolizumab Approved Indications
Table 20: Avelumab Approved Indications
Table 21: Durvalumab Approved Indications
Table 22: Global Market of Checkpoint Inhibitors, by Region, Through 2025
Table 23: Global Market Shares for Checkpoint Inhibitors, by Region, 2019
Table 24: Global Market for Interferons and Interleukins, Through 2025
Table 25: Global Market for Interferons and Interleukins, by Region, Through 2025
Table 26: Global Market for Immunotherapy, by Therapeutic Area, Through 2025
Table 27: Global Market for Immunotherapy Drugs, by Region, Through 2025
Table 28: North American Market for Immunotherapy Drugs, by Country, Through 2025
Table 29: North American Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 30: European Market for Immunotherapy Drugs, by Country, Through 2025
Table 31: European Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 32: Asia-Pacific Market for Immunotherapy Drugs, by Country, Through 2025
Table 33: Asia-Pacific Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 34: Chinese Market Statistics
Table 35: Japanese Market Statistics
Table 36: AbbVie: Product Portfolio
Table 37: Amgen: Product Portfolio
Table 38: AstraZeneca: Product Portfolio
Table 39: Bayer AG: Product Portfolio
Table 40: Johnson & Johnson: Product Portfolio
Table 41: Viatris: Product Portfolio
Table 42: Novartis AG: Product Portfolio
Table 43: Pfizer: Product Portfolio
Table 44: Pfizer: Pipeline Product Portfolio
List of Figures
Summary Figure A: Global Market for Immunotherapy Drugs, by Product Type, 2019-2025
Summary Figure B: Global Market for Immunotherapy Drugs, by Region, 2019-2025
Figure 1: Annual Incidence and Mortality Data for Lung Cancer in the U.S., 1990-2020
Figure 2: Annual Incidence and Mortality Data for Lung Cancer in Five EU Countries, 1975-2020
Figure 3: Annual Incidence and Mortality Data for Lung Cancer in the Rest of the World, 1975-2020
Figure 4: Five-Year Survival Rates, by Lung Cancer Stage
Figure 5: Annual Incidence and Mortality Data for Breast Cancer in the U.S., 1975-2020
Figure 6: Annual Incidence and Mortality Data for Breast Cancer in Five E.U. Countries., 1975-2020
Figure 7: Annual Incidence and Mortality Data for Breast Cancer in Japan, 1975-2020
Figure 8: Annual Incidence and Mortality Data for Breast Cancer in the Rest of the World, 1975-2020
Figure 9: Five-Year Survival Rates, by Breast Cancer Stage
Figure 10: Annual Incidence and Mortality Data for Colorectal Cancer in the U.S., 1975-2020
Figure 11: Annual Incidence and Mortality Data for Colorectal Cancer in Five EU Countries, 1975-2020
Figure 12: Annual Incidence and Mortality Data for Colorectal Cancer in Japan, 1975-2020
Figure 13: Annual Incidence and Mortality Data for Colorectal Cancer in the Rest of the World, 1975-2020
Figure 14: Five-Year Survival Rates, by Colorectal Cancer Stage
Figure 15: Annual Incidence and Mortality Data for Stomach Cancer in the U.S., 1975-2020
Figure 16: Annual Incidence and Mortality Data for Stomach Cancer in Five EU Countries, 1975-2012
Figure 17: Annual Incidence and Mortality Data for Stomach Cancer in Japan, 1975-2020
Figure 18: Annual Incidence and Mortality Data for Stomach Cancer in the Rest of the World, 1975-2020
Figure 19: Five-Year Survival Rates, by Stomach Cancer Stage
Figure 20: Annual Incidence and Mortality Data for Leukemia in the U.S., 1975-2020
Figure 21: Annual Incidence and Mortality Data for Leukemia in Five EU Countries, 1975-2020
Figure 22: Annual Incidence and Mortality Data for Leukemia in Japan, 1975-2020
Figure 23: Annual Incidence and Mortality Data for Leukemia in the Rest of the World, 1975-2020
Figure 24: Potential Targets for Checkpoint Inhibition in Clinical Evaluation
Figure 25: SWOT Analysis of Immunotherapy Market
Figure 26: Impact of COVID-19 on the Pharmaceutical Industry
Figure 27: Global Market for Immunotherapy Drugs, 2019-2025
Figure 28: Global Market Shares for Immunotherapy Drugs, by Product Type, 2019
Figure 29: Global Market Shares for Monoclonal Antibody Drugs, by Type, 2019
Figure 30: Global Market for Monoclonal Antibody Drugs, by Region, 2019-2025
Figure 31: Global Market Shares for Monoclonal Antibody Drugs, by Region, 2019
Figure 32: Pembrolizumab Comprehensive Clinical Trial Programs, by Status
Figure 33: Pembrolizumab Comprehensive Clinical Trial Programs, by Therapy
Figure 34: Pembrolizumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 35: Global Market for Pembrolizumab, 2019-2025
Figure 36: Nivolumab Comprehensive Clinical Trial Programs, by Status
Figure 37: Nivolumab Comprehensive Clinical Trial Programs, by Therapy
Figure 38: Nivolumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 39: Global Market for Nivolumab, 2019-2025
Figure 40: Atezolizumab Comprehensive Clinical Trial Programs, by Status
Figure 41: Atezolizumab Comprehensive Clinical Trial Programs, by Therapy
Figure 42: Atezolizumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 43: Global Market for Atezolizumab, 2019-2025
Figure 44: Avelumab Comprehensive Clinical Trial Programs, by Status
Figure 45: Avelumab Comprehensive Clinical Trial Programs, by Therapy
Figure 46: Avelumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 47: Global Market for Avelumab, 2019-2025
Figure 48: Durvalumab Comprehensive Clinical Trial Programs, by Status
Figure 49: Durvalumab Comprehensive Clinical Trial Programs, by Therapy
Figure 50: Durvalumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 51: Global Market for Durvalumab, 2019-2025
Figure 52: Global Market for Ipilimumab, 2019-2025
Figure 53: Global Market for Checkpoint Inhibitors, by Region, 2019-2025
Figure 54: Global Market Shares for Checkpoint Inhibitors, by Region, 2019
Figure 55: Global Market for Interferons and Interleukins, by Region, 2019-2025
Figure 56: Global Market Shares for Immunotherapy Drugs, by Region, 2019
Figure 57: North American Market Shares for Immunotherapy Drugs, by Product Type, 2019
Figure 58: European Market for Immunotherapy Drugs, by Country, 2019-2025
Figure 59: European Market for Immunotherapy Drugs, by Product Type, 2019-2025
Figure 60: Asia-Pacific Market Shares for Immunotherapy Drugs, by Product Type, 2019
Figure 61: AbbVie Inc.: Annual Revenue, 2016-2019
Figure 62: AbbVie: Revenue Share, by Region/Country, 2019
Figure 63: AbbVie: Revenue Share, by Business Unit, 2019
Figure 64: Amgen: Annual Revenue, 2016-2019
Figure 65: Amgen: Revenue Share, by Region/Country, 2019
Figure 66: Amgen: Revenue Share, by Products, 2019
Figure 67: AstraZeneca: Annual Revenue, 2016-2019
Figure 68: AstraZeneca: Revenue Share, by Region/Country, 2019
Figure 69: AstraZeneca: Revenue Share, by Business Unit, 2019
Figure 70: Bayer AG: Annual Revenue, 2016-2019
Figure 71: Bayer AG: Revenue Share, by Region, 2019
Figure 72: Bayer AG: Revenue Share, by Business Unit, 2019
Figure 73: Bristol Myers Squibb: Annual Revenue, 2016-2019
Figure 74: Bristol Myers Squibb: Revenue Share, by Region/Country, 2019
Figure 75: Bristol Myers Squibb: Revenue Share, by Brands, 2019
Figure 76: Hoffmann-La Roche: Annual Revenue, 2016-2019
Figure 77: Hoffmann-La Roche: Revenue Share in Pharmaceutical Segment, by Region/Country, 2019
Figure 78: Hoffmann-La Roche: Revenue Share, by Business Segment, 2019
Figure 79: Johnson & Johnson: Annual Revenue, 2016-2019
Figure 80: Johnson & Johnson: Revenue Share, by Region/Country, 2019
Figure 81: Johnson & Johnson: Revenue Share, by Business Unit, 2019
Figure 82: Viatris: Annual Revenue, 2016-2019
Figure 83: Viatris: Revenue Share, by Region, 2019
Figure 84: Viatris: Revenue Share, by Business Unit, 2019
Figure 85: Novartis AG: Annual Revenue, 2015-2019
Figure 86: Novartis AG: Revenue Share, by Region/Country, 2019
Figure 87: Novartis AG: Revenue Share, by Business Segment, 2019
Figure 88: Pfizer: Annual Revenue, 2016-2019
Figure 89: Pfizer: Revenue Share, by Region/Country, 2019
Figure 90: Pfizer: Revenue Share, by Business Segment, 2019
Figure 91: Vertex Pharmaceuticals: Annual Revenue, 2016-2019
Figure 92: Vertex Pharmaceuticals: R&D Expense Annual Revenue, 2017-2019
Figure 93: Vertex Pharmaceuticals: Revenue Share, by Business Segment, 2019
